Michal Horňák
During the last decade the incidence and mortality of prostate cancer has increased both worldwide and nationally. Further increase in incidence is expected due to ageing of the population. Cancer of the prostate is known for its variability in natural history and disproportionate ratio between high prevalence of clinical symptomatic carcinoma. Diagnosis of prostate cancer is based on examining prostate-specific antigen, digital rectal examination, transrectal ultrasonography and prostate biopsies. When deciding on an optimal treatment of prostate cancer the following matters need to be considered: the extent of the cancer, the age and medical condition of the patient, co-morbidity, life expectancy, effectiveness and side effects of individual treatment procedures, their effect on patient´s quality of life and individual preferences of the patients. This study points out options of treating localized, locally advanced, metastatic and hormone-refractory prostate carcinoma. It clarifies our position on prostate cancer screening at present.